[go: up one dir, main page]

CN115996727A - 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体 - Google Patents

新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体 Download PDF

Info

Publication number
CN115996727A
CN115996727A CN202180053336.2A CN202180053336A CN115996727A CN 115996727 A CN115996727 A CN 115996727A CN 202180053336 A CN202180053336 A CN 202180053336A CN 115996727 A CN115996727 A CN 115996727A
Authority
CN
China
Prior art keywords
compound
formula
compounds
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053336.2A
Other languages
English (en)
Inventor
赵焰平
王红军
冯泽旺
田娜娜
魏来
曹想荣
陈婕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CN115996727A publication Critical patent/CN115996727A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202180053336.2A 2020-08-31 2021-08-30 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体 Pending CN115996727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/112505 2020-08-31
CN2020112505 2020-08-31
PCT/CN2021/115197 WO2022042711A1 (zh) 2020-08-31 2021-08-30 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体

Publications (1)

Publication Number Publication Date
CN115996727A true CN115996727A (zh) 2023-04-21

Family

ID=80354655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053336.2A Pending CN115996727A (zh) 2020-08-31 2021-08-30 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体

Country Status (7)

Country Link
US (1) US20230303534A1 (zh)
EP (1) EP4206197A4 (zh)
JP (1) JP2023539275A (zh)
KR (1) KR20230058466A (zh)
CN (1) CN115996727A (zh)
TW (1) TW202216692A (zh)
WO (1) WO2022042711A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
CN115850152A (zh) * 2022-12-20 2023-03-28 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
CN116120292A (zh) * 2022-12-20 2023-05-16 河北鼎泰制药有限公司 一种杂质a的制备方法及其用途
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111217797A (zh) * 2017-06-30 2020-06-02 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111217797A (zh) * 2017-06-30 2020-06-02 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP4206197A4 (en) 2024-09-25
EP4206197A1 (en) 2023-07-05
WO2022042711A8 (zh) 2023-03-30
TW202216692A (zh) 2022-05-01
JP2023539275A (ja) 2023-09-13
WO2022042711A1 (zh) 2022-03-03
KR20230058466A (ko) 2023-05-03
US20230303534A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CN113563323B (zh) 一类苯并噻唑基联芳基类化合物、制备方法和用途
CN113286794B (zh) Kras突变蛋白抑制剂
CN115996727A (zh) 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体
KR102087397B1 (ko) B형 간염 바이러스의 표면항원 억제제
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
JP6617155B6 (ja) チロシンキナーゼ阻害剤およびそれを含む医薬組成物
EP2638030B1 (en) Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AU2018210196A1 (en) Pyridine compounds as allosteric SHP2 inhibitors
CA3069829A1 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
WO2015026683A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN111683662B (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
CN104860931A (zh) 丙肝病毒抑制剂及其制药用途
KR102254660B1 (ko) Ａ2ａ수용체 억제제로서의 축합 고리 유도체
JP2024089673A (ja) ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
JP7420403B2 (ja) キナーゼ阻害剤として使用される化合物およびその応用
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
JP2021523875A (ja) Ｆｇｆｒ阻害剤としてのピラジン−２（１ｈ）−オン系化合物
HUE024989T2 (en) Azaindole derivatives as ABI and SRC protein kinase inhibitors
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
TWI851336B (zh) 腺苷受體拮抗劑化合物
KR20190103286A (ko) Hdac6 선택적 억제제 및 이의 제조방법과 응용
JP7050054B2 (ja) Ｐｄｅ４阻害剤としての縮合環系化合物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CA3143813A1 (en) Cdk kinase inhibitor
CN111303128B (zh) 一种多环类化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085073

Country of ref document: HK